Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study-MedSci.cn

Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study

Witzenrath, M; Vlaar, APJ; Bauer, M; Annane, D; Heunks, L; Mourvillier, B; Vasquez, LH; Welte, T; van Paassen, P; de Bruin, S; Lim, EHT; Brouwer, MC; Tuinman, PR; Saraiva, JF; Marx, G; Lobo, SM; Boldo, R; Simon-Campos, J; Cornet, AD; Grebenyuk, A; Engelbrecht, J; Habel, M; Thielert, C; Dickinson, J; Rückinger, S; Zerbib, R; Neukirchen, D; Pilz, K; Guo, R; van de Beek, D; Riedemann, NC

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Anti-C5a Vilobelimab Reduces All-cause Mortality in Critically Ill COVID-19 Patients and in Those With Severe ARDS: A Phase 3 Randomized Double-blind, Placebo-controlled Study

科室

工具

服务